Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €44.54 EUR
Change Today +0.37 / 0.84%
Volume 488.0
As of 3:43 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

abbott laboratories (ABL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - €45.41
52 Week Low
05/26/14 - €28.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBOTT LABORATORIES (ABL)

abbott laboratories (ABL) Details

Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon. The company’s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products, such as prepared infant and follow-on formula. The company’s Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices to treat vascular diseases. Abbott Laboratories also offers blood, continuous, and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes under the FreeStyle brand; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices, and government agencies. It has strategic alliance with Fonterra. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

77,000 Employees
Last Reported Date: 02/27/15
Founded in 1888

abbott laboratories (ABL) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $2.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.0M
Executive Vice President of Medical Devices
Total Annual Compensation: $696.8K
Executive Vice President of Diagnostic Produc...
Total Annual Compensation: $690.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2014.

abbott laboratories (ABL) Key Developments

Abbott and Sekisui Collaborate to Offer Coagulation Testing for Laboratories Worldwide

Abbott and Sekisui have signed an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person's blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the US, Europe and other regions that recognise CE Mark. Coagulation testing helps clinicians in assessing people before many medical treatments and in monitoring those who take medications that can affect clotting. It is also useful in the diagnosis of blood-related disorders, such as haemophilia and thrombosis. Sales of the CP3000 are expected to begin later this year in Europe, countries that recognise CE Mark and non-regulated countries, and in the US in 2016. Abbott will have non-exclusive distribution rights with Sekisui in China, Hong Kong, Japan and Macau.

AstraZeneca to Collaborate with Abbott on Developing Companion Diagnostic Tests

AstraZeneca (UK) has entered into a collaboration deal with Abbott for developing companion diagnostic tests in order to identify patients with severe asthma, who are highly likely to benefit from a candidate drug, tralokinumab. According to the agreement, Abbott will be in charge of developing and commercialising diagnostic tests that measure serum levels of the proteins that have been identified as potential predictive biomarkers of up-regulated IL-13 in severe asthma - periostin and dipeptidyl peptidase-4 (DPP4). These diagnostic tests will be developed concurrently with the UK firm's Phase III study assessing tralokinumab for treating patients with severe, inadequately controlled asthma.

Abbott Laboratories Announces New Appointments

Abbott Laboratories announced that effective June 1, 2015, Thomas C. Freyman has been appointed Executive Vice President, Finance and Administration; John M. Capek has been appointed Executive Vice President, Ventures; and, Brian B. Yoor, has been appointed Senior Vice President, Finance and Chief Financial Officer, and will continue to report to Mr. Freyman in his new role. Mr. Yoor has served as the company’s Vice President, Investor Relations since 2013, and as Divisional Vice President, Controller Diagnostic Products from 2010 to 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABL:GR €44.54 EUR +0.37

ABL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $65.48 USD -0.17
AstraZeneca PLC 4,474 GBp +48.50
Danaher Corp $86.61 USD -0.29
Teva Pharmaceutical Industries Ltd $61.05 USD -0.37
Thermo Fisher Scientific Inc $132.15 USD -0.69
View Industry Companies

Industry Analysis


Industry Average

Valuation ABL Industry Range
Price/Earnings 37.0x
Price/Sales 3.6x
Price/Book 3.3x
Price/Cash Flow 15.3x
TEV/Sales 2.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at